Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

Despite surgical and therapeutic advances, glioblastoma multiforme (GBM) is among the most fatal primary brain tumor that is aggressive in nature. Patients with GBM have a median lifespan of just 15 months when treated with the current standard of therapy, which includes surgical resection and conco...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Ruijia, Wu, Cheng, Liu, Shiming, Zhao, Wenyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135425/
https://www.ncbi.nlm.nih.gov/pubmed/35612318
http://dx.doi.org/10.1080/10717544.2022.2075986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135425/
https://www.ncbi.nlm.nih.gov/pubmed/35612318
http://dx.doi.org/10.1080/10717544.2022.2075986

Ejemplares similares